SEC Form SC 13D/A filed by Bolt Biotherapeutics Inc. (Amendment)

SEC Form SC 13D/A filed by Bolt Biotherapeutics Inc. (Amendment)

Recent Analyst Ratings for $BOLT

$BOLT SEC Filings

$BOLT Press Releases

$BOLT Insider Trading

$BOLT Financials

$BOLT Large Ownership Changes

$BOLT Leadership Updates

$BOLT Analyst Ratings

$BOLT Insider Purchases

Recent Analyst Ratings for
$BOLT

$BOLT
SEC Filings

$BOLT
Press Releases

$BOLT
Insider Trading

$BOLT
Financials

$BOLT
Large Ownership Changes

$BOLT
Leadership Updates

$BOLT
Analyst Ratings

$BOLT
Insider Purchases

Chat with this insight

SEC Form DEF 14A filed by Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SEC Form PRE 14A filed by Bolt Biotherapeutics Inc.

Fastest customizable press release news feed in the world

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Dupont Jakob

SEC Form 4 filed by Chief Operating Officer Yonehiro Grant

Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

Live finance-specific insights

This live feed shows all institutional transactions in real time.

Live Leadership Updates

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021

Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

Bolt Biotherapeutics Announces Changes to its Board of Directors

Pacira Appoints Frank D. Lee as Chief Executive Officer

Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

Bolt Biotherapeutics downgraded by Morgan Stanley with a new price target

Bolt Biotherapeutics downgraded by Morgan Stanley

SVB Leerink reiterated coverage on Bolt Biotherapeutics with a new price target

Senior VP, Finance and PAO Nemec Sarah bought $2,835 worth of shares (5,000 units at $0.57), decreasing direct ownership by 2% to 13,863 units (SEC Form 4)

President, CEO and CFO Quinn William P. bought $2,835 worth of shares (5,000 units at $0.57) (SEC Form 4)

Quinn William P. bought $11,241 worth of shares (11,829 units at $0.95), increasing direct ownership by 48% to 36,272 units (SEC Form 4)

2/12/24 9:41:27 PM ET

$BOLT

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BOLT alert in real time by email

SC 13D/A 1 d773403dsc13da.htm SC 13D/A SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Bolt Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

097702 104

(CUSIP Number)

Louis Rambo

Proskauer Rose LLP

1001 Pennsylvania Avenue, NW

Suite 600 South

Washington, DC 20004-2533

(202) 416-6878

Robert Hopfner

Pivotal bioVenture Partners Fund I U.G.P. Ltd

501 2nd Street, Suite 200

San Francisco, CA 94107

(415) 697-1002

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 12, 2024

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 097702 104


1.		Names of Reporting Persons. Nan Fung Group Holdings Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization British Virgin Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 3,058,419
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 3,058,419

CUSIP No. 097702 104


1.		Names of Reporting Persons. NF Investment Holdings Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization British Virgin Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 3,058,419
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 3,058,419

CUSIP No. 097702 104


1.		Names of Reporting Persons. Pivotal bioVenture Partners Fund I, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,891,467
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,891,467

CUSIP No. 097702 104


1.		Names of Reporting Persons. Pivotal bioVenture Partners Fund I G.P., L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,891,467
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,891,467

CUSIP No. 097702 104


1.		Names of Reporting Persons. Pivotal bioVenture Partners Fund I U.G.P. Ltd.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,891,467
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,891,467

CUSIP No. 097702 104


1.		Names of Reporting Persons. Pivotal Partners Ltd
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,891,467
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,891,467

CUSIP No. 097702 104


1.		Names of Reporting Persons. Pivotal Life Sciences Holdings Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,891,467
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,891,467

CUSIP No. 097702 104


1.		Names of Reporting Persons. Nan Fung Life Sciences Holdings Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization British Virgin Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 2,958,419
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 2,958,419

CUSIP No. 097702 104


1.		Names of Reporting Persons. Permwell Management Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 100,000
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 100,000

CUSIP No. 097702 104


1.		Names of Reporting Persons. NFLS Beta Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization British Virgin Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,066,952
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,066,952

CUSIP No. 097702 104


1.		Names of Reporting Persons. NFLS Platform Holdings Limited
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Cayman Islands


Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 0
	8.	Shared Voting Power 1,066,952
	9.	Sole Dispositive Power 0
	10.	Shared Dispositive Power 1,066,952

Explanatory Note

This Schedule 13D/A is being filed as Amendment No. 2 (“Amendment No. 2”) to the Schedule 13D (as amended, the “Schedule 13D”) filed with the Securities and Exchange Commission on behalf of Nan Fung Group Holdings Limited, NF Investment Holdings Limited, Pivotal bioVenture Partners Fund I, L.P., Pivotal bioVenture Partners Fund I G.P., L.P., Pivotal bioVenture Partners Fund I U.G.P., Ltd., Pivotal Partners Ltd, Pivotal Life Sciences Holdings Limited, Nan Fung Life Sciences Holdings Limited, Permwell Management Limited, NFLS Beta Limited and NFLS Platform Holdings Limited.

Item 2. Identity and Background

Item 2(a) and 2(f) are amended and restated as follows:

(a) This Schedule 13D is being filed by each of the following persons (each, a “Reporting Person”):

(i) Nan Fung Group Holdings Limited (“NFGHL”)

(ii) NF Investment Holdings Limited (“NFIHL”)

(iii) Nan Fung Life Sciences Holdings Limited (“Nan Fung Life Sciences”)

(iv) Pivotal bioVenture Partners Fund I, L.P. (“Pivotal”)

(v) Pivotal bioVenture Partners Fund I G.P., L.P. (“Pivotal GP”)

(vi) Pivotal bioVenture Partners Fund I U.G.P. Ltd. (the “Ultimate General Partner”)

(vii) Pivotal Partners Ltd (“Pivotal Partners”)

(viii) Pivotal Life Sciences Holdings Limited (“Pivotal Life Sciences,” and together with Pivotal, Pivotal GP, Ultimate General Partner, and Pivotal Partners, the “Pivotal Entities”)

(ix) Permwell Management Limited (“Permwell”)

(x) NFLS Beta Limited (“NFLS”)

(xi) NFLS Platform Holdings Limited (“NFLS Platform”)

Pivotal GP is the general partner of Pivotal, and Ultimate General Partner is the general partner of Pivotal GP. Ultimate General Partner is wholly-owned by Pivotal Partners. Pivotal Partners is wholly-owned by Pivotal Life Sciences. Pivotal Life Sciences is wholly owned by Nan Fung Life Sciences, and Nan Fung Life Sciences is wholly-owned by NFIHL, which is wholly owned by NFGHL. Permwell is wholly-owned by NFIHL. NFLS is wholly-owned by NFLS Platform, which is wholly-owned by Nan Fung Life Sciences. The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal, Permwell, and NFLS. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Heqing Huang and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached to Amendment No. 1 to the Schedule 13D as Exhibit 1.

(f) Pivotal is a Cayman Islands exempted limited partnership. Pivotal GP is a Cayman Islands exempted limited partnership. Ultimate General Partner is a Cayman Islands exempted company. Pivotal Partners is a Cayman Islands exempted company. Pivotal Life Sciences is a Cayman Islands exempted company. Nan Fung Life Sciences, NFIHL and NFGHL are incorporated in the British Virgin Islands. Permwell is incorporated in the Cayman Islands. NFLS is incorporated in the British Virgin Islands and NFLS Platform is incorporated in the Cayman Islands. Mr. Kam Chung Leung, Mr. Pui Kuen Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are citizens of the Hong Kong Special Administrative Region of the People’s Republic of China. Ms. Heqing Huang is a citizen of the People’s Republic of China. Mr. Frank Kai Shui Seto is a citizen of Canada. Mr. Vincent Sai Sing Cheung and Ms. Vanessa Tih Lin Cheung are citizens of the United Kingdom.

Item 5. Interest in Securities of the Issuer

Item 5 of the Schedule 13D is amended and restated as follows:

(a)

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 37,965,870 outstanding shares of Common Stock, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

In addition, Mr. Kam Chung Leung directly owns 173,698 shares of Common Stock.

(b)	The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

(c)	None of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days.

(d)	No person (other than the Reporting Persons) is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this Schedule 13D.

(e)	Not applicable.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Dated: February 12, 2024

NAN FUNG GROUP HOLDINGS LIMITED

By:		/s/ Tang Chun Wai Nelson
Name:		Tang Chun Wai Nelson
Title:		Director

NF INVESTMENT HOLDINGS LIMITED

By:		/s/ Tang Chun Wai Nelson
Name:		Tang Chun Wai Nelson
Title:		Director

NAN FUNG LIFE SCIENCES HOLDINGS LIMITED

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director


PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.

By:	PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.
	Its General Partner,

	By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P., LTD.
	Its General Partner,

	By:	/s/ Robert Hopfner
	Name:	Robert Hopfner
	Title:	Authorized Signatory

PIVOTAL BIOVENTURE PARNTERS FUND I G.P., L.P.

By:	PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD
	Its General Partner,

	By:	/s/ Robert Hopfner
	Name:	Robert Hopfner
	Title:	Authorized Signatory


PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

By:		/s/ Robert Hopfner
Name:		Robert Hopfner
Title:		Authorized Signatory

PIVOTAL PARTNERS LTD

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director

PIVOTAL LIFE SCIENCES HOLDINGS LIMITED

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director

PERMWELL MANAGEMENT LIMITED

By:		/s/ Tang Chun Wai Nelson
Name:		Tang Chun Wai Nelson
Title:		Director

NFLS BETA LIMITED

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director

NFLS PLATFORM HOLDINGS LIMITED

By:		/s/ Sun Xintong
Name:		Sun Xintong
Title:		Director

Get the next $BOLT alert in real time by email

Date	Price Target	Rating	Analyst
1/6/2022	$45.00 → $11.00	Overweight → Equal-Weight	Morgan Stanley
1/6/2022		Overweight → Equal-Weight	Morgan Stanley
11/10/2021	$35.00 → $33.00	Outperform	SVB Leerink
8/16/2021	$34.00 → $35.00	Outperform	SVB Leerink

Aggregate Amount Beneficially Owned by Each Reporting Person

3,058,419

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

☐

Percent of Class Represented by Amount in Row (11)

8.1%

Type of Reporting Person (See Instructions)

CO